KMDA (Kamada Corp) Market Value to Book Value Ratio

Kamada Corp (KMDA) - corporate logo

Kamada Ltd. (KMDA) relies on exclusive government agreements with Israel and the US, leading the development of orphan plasma-derived therapies. A flawless brand image and the trust of the global community confirm the company's superior scientific expertise. This price chart illustrates the dynamics of an asset whose operating margin of 1.71 is supported by diversified raw material procurement channels and strict temperature control during transport.

Market Capitalization to Net Assets: Kamada Pharma (KMDA) for 07/04/2022 - 10/28/2026
Finished products of Kamada Ltd

The resilience of Kamada Ltd. (KMDA) biopharmaceutical supply chains forms the basis of net assets, which in this metric are compared with the current market price of the business. Analyzing the ratio of the company's market capitalization to its book capitalization allows for an assessment of the capital quality premium, determining the extent to which market expectations exceed the confirmed value of the company's resources.

Direct competitors

VRTX: Market Capitalization to Book Value Ratio|ALNY (alnylam.com) - Market Capitalization to Book Value Ratio|INSM: Market Value to Book Value Ratio|Market Capitalization to Book Value UTHR|BMRN - Market Value to Book Value Ratio|Market Capitalization to Net Assets BridgeBio Corp (BBIO)|BGM: Market Capitalization to Book Value Ratio|Market-to-Book Ratio cogentbio.com COGT|XERS: Market Capitalization to Book Value Ratio|KROS - Market Cap to Net Assets Ratio|Arcturus Pharma - Market Capitalization to Book Value Ratio|Eton Corp (ETON) - Market Capitalization to Book Value|FULC (Fulcrum Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio ABEO|Market Value to Book Value Ratio Mereo BioPharma (MREO)|Market Value to Book Value Ratio Protalix BioTherapeutics Inc. (PLX)|Market Capitalization to Book Value Ratio PLRX|APLT - Market Capitalization to Book Value|Market Cap to Net Assets Ratio Rein Therapeutics Inc|GELS - Market Capitalization to Net Assets|Market Capitalization to Book Value Ratio AYTU|Chemomab Therapeutics Ltd. (CMMB) - Market-to-Book Ratio|Market Capitalization to Book Value Ratio SRx Health Solutions Inc (SRXH)|Capitalization to Book Value Ratio Polyrizon Ltd. (PLRZ)|Aeterna Zentaris (AEZS) - Market Cap to Net Assets Ratio|Market Value to Book Value CYTH (cyclotherapeutics.com)|Inozyme Pharma (INZY) - Market Value to Book Value Ratio|Market Capitalization to Net Assets Reneo Pharmaceuticals Inc. RPHM|Market Capitalization to Book Value Ratio Aeterna Zentaris (CSCI)